Cantor Fitzgerald raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $130 from $95 and keeps an Overweight rating on the shares. Mirum’s proposed acquisition of Bluejay Therapeutics for $250M in cash, $300M in stock, and $200M in tiered milestone payments is a “steal,” the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals Announces Merger with Bluejay Therapeutics
- Mirum Pharmaceuticals to acquire Bluejay Therapeutics in cash, stock transaction
- Mirum Pharmaceuticals enrolls first patient in Phase 2 BLOOM study of MRM-3379
- Mirum Pharmaceuticals: Strategic Positioning and Strong Defense Justify Buy Rating
- Mirum Pharmaceuticals Faces Patent Challenge from Sandoz